Pear Therapeutics and Thimble Point Acquisition announced a definitive business combination agreement that, if completed, would give the merged entity a pro forma equity value of approximately $1.6 billion.
The combined company would be named Pear Holdings and list on the Nasdaq under PEAR.
The deal is expected to provide approximately $400 million in gross proceeds to Pear, including up to $276 million of funds held in Thimble Point’s trust and a $125 million upsized PIPE.
Pear develops prescription digital therapeutics (PDTs), which are software applications designed to collect real world data for use by prescribing clinicians and by payors and health systems for population health management. Read more.
